Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.lauruslabs.com | |
Market Cap | 31,027.13 Cr. | |
Enterprise Value(EV) | 32,683.22 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 15.58 | Trailing Twelve Months Ending 2022-06 |
Price-Earning Ratio (PE) | 37.05 | Trailing Twelve Months Ending 2022-06 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-06 |
Book Value / Share | 66.89 | Trailing Twelve Months Ending 2022-06 |
Price to Book Value | 8.63 | Calculated using Price: 577.40 |
Dividend Yield | 0.35 | Period Ending 2022-03 |
No. of Shares Subscribed | 53.74 Cr. | 537,359,335 Shares |
FaceValue | 2 | |
Company Profile | ||
Laurus Labs offers broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. Their major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. |
1 Day |
|
+1.34% |
1 Week |
|
+4.69% |
1 Month |
|
+11.95% |
3 Month |
|
+4.62% |
6 Month |
|
+6.51% |
1 Year |
|
-15.80% |
2 Year |
|
+180.12% |
5 Year |
|
+436.94% |
10 Year |
|
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 33.42 | 14.47 | 18.65 | 18.12 | 11.97 | 6.19 | 15.39 | 45.15 | 28.05 | |
Return on Capital Employed (%) | 19.96 | 13.74 | 16.35 | 16.52 | 13.68 | 8.22 | 14.14 | 39.82 | 25.97 | |
Return on Assets (%) | 7.64 | 4.31 | 6.61 | 8.05 | 6.04 | 3.00 | 7.34 | 20.87 | 13.09 |
Particulars | 9 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Shh. Funds | 358 | 722 | 857 | 1,330 | 1,483 | 1,558 | 1,770 | 2,598 | 3,351 | |
Non Curr. Liab. | 204 | 364 | 428 | 132 | 174 | 295 | 214 | 693 | 928 | |
Curr. Liab. | 711 | 802 | 884 | 1,121 | 1,307 | 1,424 | 1,692 | 2,457 | 2,681 | |
Minority Int. | 3 | 8 | ||||||||
Equity & Liab. | 1,273 | 1,888 | 2,169 | 2,584 | 2,964 | 3,278 | 3,676 | 5,751 | 6,968 | |
Non Curr. Assets | 697 | 1,024 | 1,166 | 1,444 | 1,716 | 1,815 | 1,864 | 2,676 | 3,623 | |
Curr. Assets | 575 | 862 | 1,003 | 1,140 | 1,248 | 1,463 | 1,812 | 3,075 | 3,345 | |
Misc. Exp. not W/O | 2 | 2 | ||||||||
Total Assets | 1,273 | 1,888 | 2,169 | 2,584 | 2,964 | 3,278 | 3,676 | 5,751 | 6,968 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-06 Rs. Cr. TTM |
Net Sales | 1,160 | 1,327 | 1,778 | 1,905 | 2,056 | 2,292 | 2,832 | 4,814 | 4,936 | 5,196 | |
Other Income | 9 | 34 | 4 | 33 | 29 | 16 | 6 | 24 | 15 | 11 | |
Total Income | 1,169 | 1,361 | 1,782 | 1,938 | 2,085 | 2,308 | 2,838 | 4,837 | 4,951 | 5,207 | |
Total Expenditure | -956 | -1,131 | -1,415 | -1,497 | -1,643 | -1,936 | -2,267 | -3,263 | -3,513 | -3,715 | |
PBIDT | 212 | 229 | 367 | 441 | 443 | 372 | 570 | 1,574 | 1,438 | 1,492 | |
Interest | -59 | -101 | -111 | -100 | -80 | -88 | -90 | -68 | -102 | -105 | |
Depreciation | -33 | -62 | -86 | -106 | -125 | -164 | -187 | -205 | -251 | -264 | |
Taxation | -24 | 2 | -35 | -44 | -70 | -26 | -38 | -317 | -251 | -280 | |
Exceptional Items | |||||||||||
PAT | 97 | 68 | 134 | 191 | 168 | 94 | 255 | 984 | 832 | 843 | |
Minority Interest | 0 | -5 | -5 | ||||||||
Share Associate | 0 | 0 | -1 | 0 | -1 | ||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 97 | 68 | 134 | 190 | 168 | 94 | 255 | 984 | 828 | 837 | |
Adjusted EPS | 13 | 9 | 17 | 4 | 3 | 2 | 5 | 18 | 15 | 16 |
Particulars | 9 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 121 | -65 | 182 | 332 | 342 | 298 | 347 | 733 | 911 | |
Cash Fr. Inv. | -312 | -397 | -312 | -289 | -384 | -253 | -221 | -941 | -914 | |
Cash Fr. Finan. | 203 | 486 | 103 | -54 | 42 | -45 | -128 | 255 | 30 | |
Net Change | 12 | 24 | -27 | -10 | 1 | 0 | -1 | 47 | 27 | |
Cash & Cash Eqvt | 15 | 40 | 13 | 2 | 3 | 3 | 2 | 48 | 75 |
Wed, 03 Aug 2022
Transcript of Analysts/Institutional Investor Meet/Con. Call
|
|
Tue, 02 Aug 2022
Transcript of Analysts/Institutional Investor Meet/Con. Call
|
|
Fri, 29 Jul 2022
Recording of Analysts/Institutional Investor Meet/Con. Call
|
Tue, 16 Aug 2022 |
|
|
|
|
|